Physician profile
Charles E Lowe
NPI 1104854207
$11,289.95
in general payments reported to CMS, 2019-2025
11 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $166 · 2021: $10K · 2022: $137 · 2023: $39.72 · 2024: $143 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $299 · Education: $23.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $299.30 |
| Education | $23.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $10,202.81 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $494.15 | 2019-2025 | Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $183.86 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $130.44 | 2020-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $80.59 | 2025 | |
| Merck Sharp & Dohme LLC | $66.31 | 2019 | |
| Genzyme Corporation | $47.98 | 2019-2023 | |
| Genentech USA, INC. | $30.23 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $22.06 | 2025 | Neffy |
| Optinose US, INC. | $16.25 | 2024 | |
| Alk-Abello, INC | $15.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.